UY35142A - Derivados de triazolopirazinas como inhibidores de brd4 - Google Patents
Derivados de triazolopirazinas como inhibidores de brd4Info
- Publication number
- UY35142A UY35142A UY0001035142A UY35142A UY35142A UY 35142 A UY35142 A UY 35142A UY 0001035142 A UY0001035142 A UY 0001035142A UY 35142 A UY35142 A UY 35142A UY 35142 A UY35142 A UY 35142A
- Authority
- UY
- Uruguay
- Prior art keywords
- triazolopirazins
- brd4
- inhibitors
- derivatives
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
- C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención comprende compuestos de la fórmula general I en donde los grupos R1 a R3 tienen los significados dados en las reivindicaciones y la memoria descriptiva. Los compuestos de la invención son apropiados para el tratamiento de enfermedades caracterizadas por una proliferación celular excesiva o anormal, preparaciones farmacéuticas que contienen tales compuestos y sus usos como un medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192987 | 2012-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35142A true UY35142A (es) | 2014-05-30 |
Family
ID=47177838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035142A UY35142A (es) | 2012-11-16 | 2013-11-15 | Derivados de triazolopirazinas como inhibidores de brd4 |
Country Status (38)
Country | Link |
---|---|
US (3) | US9266891B2 (es) |
EP (1) | EP2925761B1 (es) |
JP (1) | JP5959754B2 (es) |
KR (1) | KR102190087B1 (es) |
CN (2) | CN107266455B (es) |
AP (1) | AP2015008418A0 (es) |
AR (1) | AR093515A1 (es) |
AU (1) | AU2013346809B9 (es) |
BR (1) | BR112015011158B1 (es) |
CA (1) | CA2891193C (es) |
CL (1) | CL2015001250A1 (es) |
CY (1) | CY1119387T1 (es) |
DK (1) | DK2925761T3 (es) |
EA (1) | EA029051B1 (es) |
ES (1) | ES2641465T3 (es) |
GE (1) | GEP201706624B (es) |
HK (1) | HK1210169A1 (es) |
HR (1) | HRP20171474T1 (es) |
HU (1) | HUE034467T2 (es) |
IL (1) | IL238400A (es) |
LT (1) | LT2925761T (es) |
MA (1) | MA38099B1 (es) |
ME (1) | ME02857B (es) |
MX (1) | MX363587B (es) |
MY (1) | MY191358A (es) |
NZ (1) | NZ707203A (es) |
PE (1) | PE20151023A1 (es) |
PH (1) | PH12015501074A1 (es) |
PL (1) | PL2925761T3 (es) |
PT (1) | PT2925761T (es) |
RS (1) | RS56333B1 (es) |
SG (1) | SG11201503856XA (es) |
SI (1) | SI2925761T1 (es) |
TN (1) | TN2015000187A1 (es) |
TW (1) | TWI619717B (es) |
UA (1) | UA114739C2 (es) |
UY (1) | UY35142A (es) |
WO (1) | WO2014076237A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
US9428513B2 (en) * | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
CN105669733A (zh) * | 2016-01-29 | 2016-06-15 | 上海毕路得医药科技有限公司 | 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法 |
AU2017359288A1 (en) * | 2016-11-14 | 2019-05-30 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer |
CN109111437B (zh) * | 2017-06-22 | 2022-03-04 | 中国科学院广州生物医药与健康研究院 | 一种苯并[d]异恶唑类化合物及其制备方法和应用 |
JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
SG11202000431PA (en) | 2017-07-18 | 2020-02-27 | Nuvation Bio Inc | 1,8-naphthyridinone compounds and uses thereof |
EP3743067A1 (en) * | 2018-01-25 | 2020-12-02 | Boehringer Ingelheim International GmbH | Combination treatment of acute myeloid leukemia |
CA3095760A1 (en) | 2018-04-19 | 2019-10-24 | Ember Technologies, Inc. | Portable cooler with active temperature control |
CN108794484B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | [1,2,4]***并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
EP3873474A4 (en) | 2018-10-30 | 2022-07-13 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS BET Inhibitors |
WO2020146394A2 (en) | 2019-01-11 | 2020-07-16 | Ember Technologies, Inc. | Portable cooler with active temperature control |
EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11668508B2 (en) | 2019-06-25 | 2023-06-06 | Ember Technologies, Inc. | Portable cooler |
CA3143365A1 (en) | 2019-06-25 | 2020-12-30 | Ember Technologies, Inc. | Portable cooler |
US11162716B2 (en) | 2019-06-25 | 2021-11-02 | Ember Technologies, Inc. | Portable cooler |
MX2022000050A (es) | 2019-07-02 | 2022-05-24 | Nuvation Bio Inc | Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). |
CN112470190A (zh) * | 2019-09-25 | 2021-03-09 | 深透医疗公司 | 用于改进低剂量体积对比增强mri的***和方法 |
KR20220077138A (ko) | 2019-09-30 | 2022-06-08 | 쿄와 기린 가부시키가이샤 | Bet 분해제 |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
WO2022184664A1 (en) * | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
WO2022204452A1 (en) * | 2021-03-26 | 2022-09-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915968A (en) | 1973-09-21 | 1975-10-28 | Lepetit Spa | Triazolopyridazines |
AU9651198A (en) | 1997-11-11 | 1999-05-31 | Ono Pharmaceutical Co. Ltd. | Fused pyrazine compounds |
EA015754B1 (ru) | 2005-12-21 | 2011-12-30 | Янссен Фармацевтика, Н.В. | Триазолопиридазины в качестве модуляторов тирозинкиназы |
WO2008109104A1 (en) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
AU2008339572B2 (en) | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
WO2009084693A1 (ja) * | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
JP5524343B2 (ja) | 2009-11-05 | 2014-06-18 | グラクソスミスクライン エルエルシー | ベンゾジアゼピンブロモドメイン阻害剤 |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
US9193723B2 (en) | 2012-05-11 | 2015-11-24 | Abbvie Inc. | NAMPT inhibitors |
US20140107107A1 (en) * | 2012-09-28 | 2014-04-17 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
JP6370368B2 (ja) | 2013-03-27 | 2018-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Brd4阻害剤としてのインドリノン類似体 |
EP2978758B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Dihydroquinazolinone analogues as brd4 inhibitors |
US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
US9428515B2 (en) | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
-
2013
- 2013-11-11 US US14/076,510 patent/US9266891B2/en active Active
- 2013-11-15 MY MYPI2015001310A patent/MY191358A/en unknown
- 2013-11-15 HU HUE13789833A patent/HUE034467T2/en unknown
- 2013-11-15 PT PT137898334T patent/PT2925761T/pt unknown
- 2013-11-15 LT LTEP13789833.4T patent/LT2925761T/lt unknown
- 2013-11-15 AP AP2015008418A patent/AP2015008418A0/xx unknown
- 2013-11-15 UA UAA201505745A patent/UA114739C2/uk unknown
- 2013-11-15 PE PE2015000635A patent/PE20151023A1/es active IP Right Grant
- 2013-11-15 BR BR112015011158-0A patent/BR112015011158B1/pt active IP Right Grant
- 2013-11-15 ME MEP-2017-190A patent/ME02857B/me unknown
- 2013-11-15 EP EP13789833.4A patent/EP2925761B1/en active Active
- 2013-11-15 WO PCT/EP2013/073946 patent/WO2014076237A1/en active Application Filing
- 2013-11-15 SI SI201330773T patent/SI2925761T1/sl unknown
- 2013-11-15 JP JP2015542274A patent/JP5959754B2/ja active Active
- 2013-11-15 AU AU2013346809A patent/AU2013346809B9/en active Active
- 2013-11-15 SG SG11201503856XA patent/SG11201503856XA/en unknown
- 2013-11-15 AR ARP130104230A patent/AR093515A1/es active IP Right Grant
- 2013-11-15 PL PL13789833T patent/PL2925761T3/pl unknown
- 2013-11-15 GE GEAP201313859A patent/GEP201706624B/en unknown
- 2013-11-15 DK DK13789833.4T patent/DK2925761T3/en active
- 2013-11-15 RS RS20170907A patent/RS56333B1/sr unknown
- 2013-11-15 MA MA38099A patent/MA38099B1/fr unknown
- 2013-11-15 TW TW102141767A patent/TWI619717B/zh active
- 2013-11-15 NZ NZ70720313A patent/NZ707203A/en unknown
- 2013-11-15 KR KR1020157012600A patent/KR102190087B1/ko active IP Right Grant
- 2013-11-15 UY UY0001035142A patent/UY35142A/es not_active Application Discontinuation
- 2013-11-15 CN CN201710479950.0A patent/CN107266455B/zh active Active
- 2013-11-15 CN CN201380059254.4A patent/CN104870448B/zh active Active
- 2013-11-15 CA CA2891193A patent/CA2891193C/en active Active
- 2013-11-15 EA EA201500536A patent/EA029051B1/ru not_active IP Right Cessation
- 2013-11-15 ES ES13789833.4T patent/ES2641465T3/es active Active
- 2013-11-15 MX MX2015005953A patent/MX363587B/es unknown
-
2015
- 2015-04-21 IL IL238400A patent/IL238400A/en active IP Right Grant
- 2015-05-08 CL CL2015001250A patent/CL2015001250A1/es unknown
- 2015-05-14 PH PH12015501074A patent/PH12015501074A1/en unknown
- 2015-05-14 TN TNP2015000187A patent/TN2015000187A1/fr unknown
- 2015-11-09 HK HK15111012.4A patent/HK1210169A1/xx unknown
-
2016
- 2016-01-14 US US14/995,578 patent/US10328074B2/en active Active
-
2017
- 2017-09-26 CY CY20171101012T patent/CY1119387T1/el unknown
- 2017-10-02 HR HRP20171474TT patent/HRP20171474T1/hr unknown
-
2019
- 2019-04-19 US US16/389,062 patent/US11077107B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35142A (es) | Derivados de triazolopirazinas como inhibidores de brd4 | |
UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
DOP2014000188A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
CO6781507A2 (es) | Novedosos derivados heterociclicos | |
CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
DOP2015000241A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
ECSP14013215A (es) | Compuestos novedosos | |
GT201500190A (es) | Lactamas fusionadas de arilo y heteroarilo | |
CR20150326A (es) | Inhibidores de autotaxina | |
CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
ECSP14018375A (es) | 6-alquinilo piridinas como miméticos smac | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
GT201500069A (es) | Piridinonas bicìclicas novedosas | |
UY35711A (es) | Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
DOP2015000170A (es) | Compuestos químicos | |
UY35710A (es) | 6-alquinilpiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
UY35922A (es) | Derivados de sulfonamidas tricíclicas | |
UY33877A (es) | Derivados de 5-alquinil-piridinas con efecto inhibitorio sobre la actividad de pi3k-alfa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220315 |